Thérapies de Conversion

Pratiques visant à modifier l'orientation sexuelle ou l'identité de genre, illégales en France depuis la loi n°2022-92, et leurs effets psychologiques documentés.

500 articles disponibles

conversion therapy
sexual orientation change effort
SOCE harm
gender identity conversion
reparative therapy mental health
ex-gay therapy
conversion practice religious

Imaging-defined complete response to immune checkpoint inhibitors predicts durable survival in advanced hepatocellular carcinoma.

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized advanced hepatocellular carcinoma (HCC) treatment, yet complete responses (CRs) remain rare, and their long-term outcomes are poorly…

Thérapies de Conversion
Shao, Y., Yuan, J., Liu, Y., & Wang, F. (2025). Imaging-defined complete response to immune checkpoint inhibitors predicts durable survival in advanced hepatocellular carcinoma.. Front Oncol, 15, 1687449. https://doi.org/10.3389/fonc.2025.1687449

Case Report: Successful Surgical Resection of PVTT Vp4 Hepatocellular Carcinoma Following Hepatic Arterial Infusion Chemotherapy Combined with Cadonilimab Plus Donafenib.

OBJECTIVE: To evaluate the potential and efficacy of hepatic artery infusion chemotherapy combined with the PD-1/CTLA-4 bispecific antibody cadonilimab and the multi-kinase inhibitor donafenib in conv…

Thérapies de Conversion
Chen, S., Wei, Y., Liao, X., Yang, C., Zhu, G., Han, C., Su, H., & Peng, T. (2025). Case Report: Successful Surgical Resection of PVTT Vp4 Hepatocellular Carcinoma Following Hepatic Arterial Infusion Chemotherapy Combined with Cadonilimab Plus Donafenib.. Pharmgenomics Pers Med, 18, 279-286. https://doi.org/10.2147/PGPM.S555061

Case Report: Dual checkpoint inhibition with bevacizumab yields dramatic response in synchronous double primary HCC and ICC with lung metastasis.

BACKGROUND: Due to its rarity, synchronous double primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma (sdpHCC-ICC) presents significant challenges for preoperative diagnosis and is la…

Thérapies de Conversion
He, Y. C., Dai, X. Y., Lv, Y. H., Yang, X. J., Xie, Q. Y., Xie, S. N., Cai, Y. S., Gao, F. W., & Lan, T. (2025). Case Report: Dual checkpoint inhibition with bevacizumab yields dramatic response in synchronous double primary HCC and ICC with lung metastasis.. Front Oncol, 15, 1670818. https://doi.org/10.3389/fonc.2025.1670818

Spontaneous Rupture of Hepatocellular Carcinoma: Pathogenesis, Clinical Management, Prognostic Factors, and Future Directions.

Spontaneous rupture of hepatocellular carcinoma (srHCC) is a life-threatening complication with complex pathophysiology and heterogeneous clinical presentations. This review aims to provide an up-to-d…

Thérapies de Conversion
Cheng, Y., Ye, F., & Chen, Y. (2025). Spontaneous Rupture of Hepatocellular Carcinoma: Pathogenesis, Clinical Management, Prognostic Factors, and Future Directions.. J Hepatocell Carcinoma, 12, 2421-2428. https://doi.org/10.2147/JHC.S540510

Advancing human rights, health equity, and equitable health policy with LGBTQ+ people: An American Academy of Nursing consensus paper.

Health disparities among LGBTQ+ people arise from sociocultural contexts of gender oppression. Complex historical, legal, and policy landscapes perpetuate inequities through discriminatory legislation…

Thérapies de Conversion
Phillips, J. C., Cornelius, J. B., Neira, P. M., Hein, L., Ducar, D., Rose, C. D., Rosa, W. E., Ballout, S., Nagel, D. A., Millender, E. I. F., Neft, M. W., Jablonski, R. A., Murray, T. A., Stamps, D. C., Brous, E., & Keepnews, D. M. (2025). Advancing human rights, health equity, and equitable health policy with LGBTQ+ people: An American Academy of Nursing consensus paper.. Nurs Outlook, 73(5), 102496. https://doi.org/10.1016/j.outlook.2025.102496

Correction: Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma.

[This corrects the article DOI: 10.3389/fimmu.2025.1451965.].

Thérapies de Conversion
Wang, Z., Zhang, C., Yin, J., & Li, N. (2025). Correction: Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma.. Front Immunol, 16, 1647890. https://doi.org/10.3389/fimmu.2025.1647890

Tumor marker pseudoprogression and immune-related cholangitis during conversion therapy for massive hepatocellular carcinoma: a case report.

Cases with massive (diameter ≥10 cm) hepatocellular carcinomas (HCCs) are uncommon and typically have poor outcomes; however, conversion therapy offers a beacon of hope for remission in patients with …

Thérapies de Conversion
Zhang, X., Zhang, L., Zhao, S., Dai, L., Li, H., Wu, X., Yan, H., Lin, R., & Zhu, K. (2025). Tumor marker pseudoprogression and immune-related cholangitis during conversion therapy for massive hepatocellular carcinoma: a case report.. Front Immunol, 16, 1529016. https://doi.org/10.3389/fimmu.2025.1529016

Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging.

OBJECTIVE: This study aimed to assess the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and immunotherapy and explore its potential as a conversion trea…

Thérapies de Conversion
Zhang, W., Zhao, X., Gao, W., Si, T., Zou, Q., Yang, X., Xing, W., & Yu, H. (2025). Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging.. Front Immunol, 16, 1596864. https://doi.org/10.3389/fimmu.2025.1596864

Conversion therapy combined with ALPPS for the treatment of intrahepatic cholangiocarcinoma: a case report.

RATIONALE: Intrahepatic cholangiocarcinoma (ICC) is a highly malignant liver tumor with limited treatment options for advanced cases. Conversion therapy combining immunotherapy, targeted therapy, and …

Thérapies de Conversion
Tian, H., He, Q., & Wan, C. (2025). Conversion therapy combined with ALPPS for the treatment of intrahepatic cholangiocarcinoma: a case report.. Front Oncol, 15, 1542955. https://doi.org/10.3389/fonc.2025.1542955

Understanding harms associated with gender identity conversion efforts among transgender and nonbinary individuals: The role of preexisting mental well-being.

Affirmation of gender identity is critical for the mental health and overall well-being of transgender and nonbinary (TNB) persons. Gender identity conversion efforts (GICE), an outlawed practice for…

Thérapies de Conversion
Mammadli, T., Call, J., Whitfield, D. L., Holloway, B. T., & Walls, N. E. (2025). Understanding harms associated with gender identity conversion efforts among transgender and nonbinary individuals: The role of preexisting mental well-being.. Int J Transgend Health, 26(1), 157-179. https://doi.org/10.1080/26895269.2024.2333531

Prognosis predictors of hepatocellular carcinoma after hepatectomy following conversion therapy.

BACKGROUND: Hepatectomy is the optimal treatment for less than 20 % patients with hepatocellular carcinoma (HCC). A combination of hepatic artery infusion chemotherapy and systemic therapy-based conve…

Thérapies de Conversion
Liu, S., Wu, Z., Wang, C., Qiao, L., Huang, Z., Yuan, Y., Zou, R., He, W., Li, B., Yuan, Y., & Qiu, J. (2025). Prognosis predictors of hepatocellular carcinoma after hepatectomy following conversion therapy.. Eur J Surg Oncol, 51(1), 109375. https://doi.org/10.1016/j.ejso.2024.109375

Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study

INTRODUCTION: Patients with advanced-stage or intermediate-stage hepatocellular carcinoma (HCC) unsuitable for transarterial chemoembolization (TACE) had poor prognoses. Recent advancements in hepatic…

Thérapies de Conversion
Kuo, L. F., Liu, W. C., Li, M. F., Huang, F. H., Chou, C. K., Chen, T. H., Tsai, Y. T., Hsu, P. I., Li, C. J., Wu, I. T., & Tsai, K. F. (2025). Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study. Oncology, 103(7), 549-561. https://doi.org/10.1159/000542291
Loading…
Loading the web debug toolbar…
Attempt #